Core T cells

Professor Angus Dalgleish, (Fellow of the Royal College of Physicians, Fellow of the Royal College of Pathologists, Fellow of Medical Science.)

Professor Dalgleish is a highly experienced doctor, physician, medical teacher, medical author and researcher with over 500 primary research publications.

He was also a pioneering researcher into HIV/AIDS.

Here we discuss the recently observed changes in cancer presentations and deaths. Some of the discussion considers this research paper noting excess cancer deaths in Japan.

Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan

https://www.cureus.com/articles/196275-increased-age-adjusted-cancer-mortality-after-the-third-mrna-lipid-nanoparticle-vaccine-dose-during-the-covid-19-pandemic-in-japan#!/

Gibo M, Kojima S, Fujisawa A, et al. (April 08, 2024) Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan. Cureus 16(4): e57860. DOI 10.7759/cureus.57860

Conclusions

Statistically significant increases in age-adjusted mortality rates of all cancer and some specific types of cancer, namely, ovarian cancer, leukemia, prostate, lip/oral/pharyngeal, pancreatic, and breast cancers, were observed in 2022 after two-thirds of the Japanese population had received the third or later dose of SARS-CoV-2 mRNA-LNP vaccine.

These particularly marked increases in mortality rates of these ERα-sensitive cancers may be attributable to several mechanisms of the mRNA-LNP vaccination,

rather than COVID-19 infection itself or reduced cancer care due to the lockdown.

Researchers have reported that the SARS-CoV-2 mRNA-LNP vaccine may pose the risk of development and progression of cancer.

Several case reports have described cancer developing or worsening after vaccination and discussed possible causal links between cancer and mRNA-LNP vaccination.

Learn more about your ad choices. Visit megaphone.fm/adchoices